# A Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia

> **NCT02952092** · PHASE3 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 303 (actual)

## Conditions studied

- Hemodialysis Chronic Kidney Disease Patients With Anemia

## Interventions

- **DRUG:** roxadustat
- **DRUG:** Darbepoetin alfa

## Key facts

- **NCT ID:** NCT02952092
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-30
- **Primary completion:** 2018-03-13
- **Final completion:** 2018-03-15
- **Target enrollment:** 303 (ACTUAL)
- **Last updated:** 2024-10-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02952092

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02952092, "A Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02952092. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*